ON
🔍
← Back to feed
FranceMedicine7 days ago

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

Incyte has announced new positive data presented at the EHA 2026 conference, indicating that its drug candidate INCA033989 achieved rapid, robust, and sustained clinical and molecular responses and was well tolerated in patients with myelofibrosis and essential thrombocythemia.

1 reports

Agence France-Presse (AFP)State / PublicCenter7 days ago
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

Incyte has announced new positive data presented at the EHA 2026 conference, indicating that its drug candidate INCA033989 achieved rapid, robust, and sustained clinical and molecular responses and was well tolerated in patients with myelofibrosis and essential thrombocythemia.

Bias read (Center): The article reports on medical research findings without taking a stance or using biased language. It focuses on clinical trial results and does not involve political commentary or framing.